You just read:

OBI Pharma Reports Topline Results From OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial In Patients With Metastatic Breast Cancer

News provided by

OBI Pharma, Inc.

22 Feb, 2016, 10:51 GMT